APA

Piha-Paul S. A., Taylor M. H., Spitz D., Schwartzberg L., Beck J. T., Bauer T. M., Meric-Bernstam F., Purkayastha D., Karpiak L., Szpakowski S. & Braiteh F. (2019). Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. : Oncotarget.

Chicago

Piha-Paul Sarina A, Taylor Matthew H, Spitz Daniel, Schwartzberg Lee, Beck J Thaddeus, Bauer Todd M, Meric-Bernstam Funda, Purkayastha Das, Karpiak Linda, Szpakowski Sebastian and Braiteh Fadi. 2019. Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. : Oncotarget.

Harvard

Piha-Paul S. A., Taylor M. H., Spitz D., Schwartzberg L., Beck J. T., Bauer T. M., Meric-Bernstam F., Purkayastha D., Karpiak L., Szpakowski S. and Braiteh F. (2019). Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. : Oncotarget.

MLA

Piha-Paul Sarina A, Taylor Matthew H, Spitz Daniel, Schwartzberg Lee, Beck J Thaddeus, Bauer Todd M, Meric-Bernstam Funda, Purkayastha Das, Karpiak Linda, Szpakowski Sebastian and Braiteh Fadi. Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. : Oncotarget. 2019.